Zipcode Bio
Zipcode Bio is a U.S.-based biotechnology company focused on next-generation nucleic acid therapeutics. The company develops organ-targeted delivery platforms for mRNA and oligonucleotide therapeutics, integrates machine learning into therapeutic design, and pursues preclinical development and collaborative programs including vaccine development and needle-free delivery approaches. Co-founders include Dr. Jason Zhang (CEO) and Dr. Drew Weissman.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Single-component nanoparticle delivery platform (proprietary)
A single-component amphiphilic particle platform used to encapsulate and deliver nucleic acid therapeutics with organ-targeting properties (described for lung and spleen delivery).
Single-component nanoparticle delivery platform (proprietary)
A single-component amphiphilic particle platform used to encapsulate and deliver nucleic acid therapeutics with organ-targeting properties (described for lung and spleen delivery).
Services
Joint research programs with external companies and research organizations to develop targeted delivery systems and therapeutic candidates.
Design and testing of delivery formulations and in vivo evaluation of tissue targeting and initial safety/tolerability.
Joint research programs with external companies and research organizations to develop targeted delivery systems and therapeutic candidates.
Design and testing of delivery formulations and in vivo evaluation of tissue targeting and initial safety/tolerability.
Expertise Areas
- Nucleic acid therapeutics
- mRNA vaccine design
- Organ-targeted delivery systems
- Preclinical development
Key Technologies
- Single-component amphiphilic particle delivery
- Ionizable amphiphilic dendrimer-like formulations
- mRNA therapeutics
- Oligonucleotide therapeutics
News & Updates
Presentation and session chairing on RNA medicine platform challenges and commercial considerations at the 4th annual mRNA-based therapeutics summit in Boston.
Presentation on transitioning preventive vaccines to therapeutic vaccines at the World Vaccine Congress in Washington, D.C.
Report of preclinical results showing lung tropism and therapeutic results using one-component ionizable amphiphilic Janus dendrimer (IAJD) delivery in animal models.
Peer-reviewed article reporting targeted delivery of TGF-β mRNA to mouse lung parenchyma using a one-component ionizable amphiphilic delivery system.
Research article describing a machine-learning model to predict 5' untranslated region function and its application to mRNA design.
Recognition and $2 million award from BARDA for a co-development concept to create a needle-free, broadly-protective mRNA influenza vaccine in collaboration with a microarray/needle-free developer.
Presentation and session chairing on RNA medicine platform challenges and commercial considerations at the 4th annual mRNA-based therapeutics summit in Boston.
Presentation on transitioning preventive vaccines to therapeutic vaccines at the World Vaccine Congress in Washington, D.C.
Report of preclinical results showing lung tropism and therapeutic results using one-component ionizable amphiphilic Janus dendrimer (IAJD) delivery in animal models.
Peer-reviewed article reporting targeted delivery of TGF-β mRNA to mouse lung parenchyma using a one-component ionizable amphiphilic delivery system.
Research article describing a machine-learning model to predict 5' untranslated region function and its application to mRNA design.
Recognition and $2 million award from BARDA for a co-development concept to create a needle-free, broadly-protective mRNA influenza vaccine in collaboration with a microarray/needle-free developer.